Zoomlogi’s Henry Ames says exception handling still hinges on experienced staff, and AI agents could gather and document details for their judgment calls.
News|Videos|September 24, 2026
Supply Chain Signal: How Policy Pressures Are Converging on Pharma
Author(s)Thani Jambulingam, PhD, Stephen Appezzato
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Advertisement
Advertisement
The third episode of Supply Chain Signal, featuring pharmaceutical supply chain expert Thanigavelan Jambulingam, Ph.D., of Saint Joseph's University's Haub School of Business, looks at the latest expansion of most favored nation (MFN) pricing, the GENEROUS Model, and examines whether Medicare negotiation, international reference pricing and tariffs, taken together, are changing how drugs are priced, made and brought to market.
Related to this article
At LogiPharma USA 2026, BMS’s Kevin Cook explains why CMO partnerships must move beyond transactions toward shared goals and KPIs.
In this week's Pharma Pulse, DHL adds six dedicated cold chain air corridors linking Europe and North America to Asia, Walmart rolls out a $0 prescription tier and rare disease Center of Excellence for its US workforce and FDA launches its Rare Disease Framework Initiative.
Cencora's Matt Sample explains how AI compares forecasts with ordering patterns to flag pharma demand shifts early, with 10% forecasting gains.
At LogiPharma USA 2026, Swisslog's Garrett Freeman explains why validation, change management and stakeholder alignment now drive automation projects.
Zoomlogi's Henry Ames explains how AI agents are resolving supply chain exceptions, from unlinked IoT trackers to after-hours escalation calls.
Octapharma USA's Kerem Tokel explains how product value and supply risk should shape freight security, and why complacency remains a persistent gap.
At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.
Advertisement
Advertisement